Identification of a potent and highly efficacious, yet slowly desensitizing CB1 cannabinoid receptor agonist

British Journal of Pharmacology

Volumn 142, Issue 3, 2004, Pages 495-500

  Luk, Terry ^a   Jin, Wenzhen ^b   Zvonok, Alexander ^c   Lu, Dai ^c   Lin, Xin Zhong ^c   Chavkin, Charles ^b   Makriyannis, Alexandros ^c   Mackie, Ken ^a,d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

^d NONE   (United States)

Author keywords

Cannabinoid; Desensitization; Efficacy; Potassium channel; Xenopus

Indexed keywords

2 ARACHIDONOYL ETHER; 2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; AM 1902; AM 2233; AM 411; AM 782; ANANDAMIDE; CANNABINOID; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR AGONIST; DRONABINOL; ETHER DERIVATIVE; G PROTEIN COUPLED RECEPTOR; INWARDLY RECTIFYING POTASSIUM CHANNEL; METHANANDAMIDE; PARTIAL AGONIST; POTASSIUM CHANNEL; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DESENSITIZATION; DRUG EFFICACY; FEMALE; NONHUMAN; OOCYTE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; XENOPUS LAEVIS;

ANIMALS; CANNABINOIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHYSIOLOGY; ENDOCANNABINOIDS; G PROTEIN-COUPLED INWARDLY-RECTIFYING POTASSIUM CHANNELS; OOCYTES; POTASSIUM CHANNELS, INWARDLY RECTIFYING; RECEPTOR, CANNABINOID, CB1; SIGNAL TRANSDUCTION; XENOPUS LAEVIS;

EID: 3042780243     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705792     Document Type: Article

References (24)

1. ALVAREZ, V.A., ARTTAMANGKUL, S., DANG, V., SALEM, A., WHISTLER, J.L., VON ZASTROW, M., GRANDY, D.K. & WILLIAMS, J.T. (2002). mu-Opioid receptors: ligand-dependent activation of potassium conductance, desensitization, and internalization. J. Neurosci., 22, 5769-5776.
2. BREIVOGEL, C.S., SELLEY, D.E. & CHILDERS, S.R. (1998). Cannabinoid receptor agonist efficacy for stimulating [35S]GTPgammaS binding to rat cerebellar membranes correlates with agonist-induced decreases in GDP affinity. J. Biol. Chem., 273, 16865-16873.
3. DASCAL, N. (1987). The use of Xenopus oocytes for the study of ion channels. CRC Crit. Rev. Biochem., 22, 317-387.
4. DUTTAROY, A. & YOBURN, B.C. (1995). The effect of intrinsic efficacy on opioid tolerance. Anesthesiology, 82, 1226-1236.
5. FAN, F., COMPTON, D.R., WARD, S., MELVÌN, L. & MARTIN, B.R. (1994). Development of cross-tolerance between delta 9-tetra-hydrocannabinol, CP 55,940 and WIN 55,212. J. Pharmacol. Exp. Ther., 271, 1383-1390.
6. HENRY, D.J. & CHAVKIN, C. (1995). Activation of inwardly rectifying potassium channels (GIRK1) by co-expressed rat brain cannabinoid receptors in Xenopus oocytes. Neurosci. Lett., 186, 91-94.
7. HILLARD, C.J. (2000). Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol. Prostaglandins Other Lipid Mediat., 61, 3-18.
8. HOWLETT, A.C., BARTH, F., BONNER, T.I., CABRAL, G., CASELLAS, P., DEVANE, W.A., FELDER, C.C., HERKENHAM, M., MACKIE, K., MARTIN, B.R., MECHOULAM, R. & PERTWEE, R.G. (2002). International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev., 54, 161-202.
9. HUESTIS, M.A., GORELICK, D.A., HEISHMAN, S.J., PRESTON, K.L., NELSON, R.A., MOOLCHAN, E.T. & FRANK, R.A. (2001). Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch. Gen. Psychiatry., 58, 322-328.
10. HUNT, C.A. & JONES, R.T. (1980). Tolerance and disposition of tetrahydrocannabinol in man. J. Pharmacol. Exp. Ther., 215, 35-44.
11. JIN, W., BROWN, S., ROCHE, J.P., HSIEH, C., CELVER, J.P., KOVOOR, A., CHAVKIN, C. & MACKIE, K. (1999). Distinct domains of the CB1 cannabinoid receptor mediate desensitization and internalization. J. Neurosci., 19, 3773-3780.
12. KENAKIN, T. (2002). Drug efficacy at G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol., 42, 349-379.
13. KOUZNETSOVA, M., KELLEY, B., SHEN, M. & THAYER, S.A. (2002). Desensitization of cannabinoid-mediated presynaptic inhibition of neurotransmission between rat hippocampal neurons in culture. Mol. Pharmacol., 61, 477-485.
14. KOVOOR, A., CELVER, J.P., WU, A. & CHAVKIN, C. (1998). Agonist induced homologous desensitization of mu-opioid receptors mediated by G protein-coupled receptor kinases is dependent on agonist efficacy. Mol. Pharmacol., 54, 704-711.
15. KOVOOR, A., HENRY, D.J. & CHAVKIN, C. (1995). Agonist-induced desensitization of the mu opioid receptor-coupled potassium channel (GIRK1). J. Biol. Chem., 270, 589-595.
16. LIMAN, E.R., TYTGAT, J. & HESS, P. (1992). Subunit stoichiometry of a mammalian K+ channel determined by construction of multimeric cDNAs. Neuron. 9, 861-871.
17. LUTTRELL, L.M. & LEFKOWITZ, R.J. (2002). The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. J. Cell Sci., 115, 455-465.
18. MACKIE, K., DEVANE, W.A. & HILLE, B. (1993). Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol. Pharmacol., 44, 498-503.
19. MATSUDA, L.A., LOLAIT, S.J., BROWNSTEIN, M.J., YOUNG, A.C. & BONNER, T.I. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 346, 561-564.
20. MCALLISTER, S.D., GRIFFIN, G., SATIN, L.S. & ABOOD, M.E. (1999). Cannabinoid receptors can activate and inhibit G protein-coupled inwardly rectifying potassium channels in a Xenopus oocyte expression system. J. Pharmacol. Exp. Ther., 291, 618-626.
21. PERTWEE, R.G., STEVENSON, L.A. & GRIFFIN, G. (1993). Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212-2 and anandamide. Br. J. Pharmacol., 110, 1483-1490.
22. SAVINAINEN, J.R., JARVINEN, T., LAINE, K. & LAITINEN, J.T. (2001). Despite substantial degradation, 2-arachidonoylglycerol is a potent full efficacy agonist mediating CB(1) receptor-dependent G-protein activation in rat cerebellar membranes. Br. J. Pharmacol., 134, 664-672.
23. SHEN, M. & THAYER, S.A. (1999). Delta9-tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture. Mol. Pharmacol., 55, 8-13.
24. WALKER, E.A. & YOUNG, A.M. (2001). Differential tolerance to antinociceptive effects of mu opioids during repeated treatment with etonitazene, morphine, or buprenorphine in rats. Psychopharmacology (Berl.), 154, 131-142.